BMJ study proves efficacy of Coala Heart Monitor as part of cryptogenic stroke management

Coala Heart Monitor

Coala Life has announced the results of a late breaking trial on cryptogenic stroke patients. In the TEASE-study, recently published in the British Medical Journal, the Coala Heart Monitor was used to evaluate 100 patients after cryptogenic stroke. Patients were recruited from two stroke units in Sweden that underwent scheduled monitoring twice daily, and when symptoms occurred, for 28 days in everyday life.

The monitoring detected previously undiagnosed atrial fibrillation (AF) in 9% of the patients, at a mean of 19.7 days after stroke. Patient compliance to the Coala monitoring protocol exceeded 90%.

The prospective, real-world TEASE-study was led by Peter Magnusson, cardiologist at the Cardiology Clinic in Region Gavleborg, and with academic affiliations to the Karolinska Institute, Stockholm, and Uppsala University, Sweden.

“The study proves the efficacy of the Coala Heart Monitor in cryptogenic stroke patients with excellent patient compliance. We recommend a hand-held, non-invasive device like Coala Heart Monitor for long-term use as the main evaluation tool in the vast majority of cryptogenic stroke cases,” said Magnusson.

The TEASE-study detected previously undiagnosed AF in 9% of cryptogenic stroke patients, using the non-invasive Coala Heart Monitor, at mean 20 days post stroke. In the CRYSTAL-AF study  it took six months to detect AF in 8.9% of cryptogenic stroke patients by using an invasive insertable cardiac monitor.


Please enter your comment!
Please enter your name here